Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Holdings Lifted by Xponance Inc.

Xponance Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,376 shares of the biopharmaceutical company’s stock after buying an additional 852 shares during the quarter. Xponance Inc.’s holdings in Regeneron Pharmaceuticals were worth $12,626,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Sunbelt Securities Inc. acquired a new stake in Regeneron Pharmaceuticals during the first quarter valued at $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter valued at $26,000. Fortitude Family Office LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $31,000. Sutton Wealth Advisors Inc. boosted its position in Regeneron Pharmaceuticals by 38.2% during the third quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 13 shares during the last quarter. Finally, Bruce G. Allen Investments LLC acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $40,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In other news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at approximately $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the completion of the transaction, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,729 shares of company stock worth $13,124,641. Company insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $7.13 during trading hours on Friday, hitting $901.12. The company had a trading volume of 83,337 shares, compared to its average volume of 489,474. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33. The firm has a market capitalization of $98.91 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 2.60 and a beta of 0.11. The firm’s fifty day moving average is $954.14 and its 200 day moving average is $890.55. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion for the quarter, compared to analyst estimates of $3.29 billion. During the same period in the prior year, the company posted $10.96 EPS. The company’s revenue was up .6% compared to the same quarter last year. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on REGN. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 12th. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price target for the company. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, UBS Group boosted their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $976.41.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.